HER2-Positive Metastatic Breast Cancer: The Treatment Shift Reshaping the Market
A Decade of Reinvention There was a time when a HER2-positive breast cancer diagnosis carried a particularly difficult outlook. The biology was aggressive, treatment options were limited, and metasta ...
Beyond Market Size: How Patient, Epidemiology & Competitive Intelligence Can Shape Oncology Investment Strategies
Background: A biopharmaceutical company was evaluating the investment potential of a targeted oncology asset. Initial market assessments appeared attractive. The indication had a sizable patient popu ...